Trial Profile
A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Lenalidomide (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Mantle-cell lymphoma
- Focus Adverse reactions
- 06 Aug 2021 Planned End Date changed from 30 Jun 2021 to 31 Mar 2025.
- 06 Aug 2021 Planned primary completion date changed from 30 Jun 2021 to 31 Mar 2025.
- 06 Aug 2021 Status changed from recruiting to active, no longer recruiting.